These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24075743)

  • 21. The epigenetic landscape in the cardiovascular complications of diabetes.
    Costantino S; Ambrosini S; Paneni F
    J Endocrinol Invest; 2019 May; 42(5):505-511. PubMed ID: 30291588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways.
    Akhmedov A; Montecucco F; Braunersreuther V; Camici GG; Jakob P; Reiner MF; Glanzmann M; Burger F; Paneni F; Galan K; Pelli G; Vuilleumier N; Belin A; Vallée JP; Mach F; Lüscher TF
    Eur Heart J; 2015 Feb; 36(8):516-26a. PubMed ID: 25336219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skewed Epigenetics: An Alternative Therapeutic Option for Diabetes Complications.
    Togliatto G; Dentelli P; Brizzi MF
    J Diabetes Res; 2015; 2015():373708. PubMed ID: 26064979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic basis of diabetic vasculopathy.
    Bhamidipati T; Kumar M; Verma SS; Mohanty SK; Kacar S; Reese D; Martinez MM; Kamocka MM; Dunn KW; Sen CK; Singh K
    Front Endocrinol (Lausanne); 2022; 13():989844. PubMed ID: 36568089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress.
    Natalicchio A; Tortosa F; Perrini S; Laviola L; Giorgino F
    Arch Physiol Biochem; 2011 Jul; 117(3):116-24. PubMed ID: 21506908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular sources of oxidative stress: implications for uremia-related cardiovascular disease.
    Zanetti M; Barazzoni R; Bosutti A; Stocca A; Grassi G; Guarnieri G
    J Ren Nutr; 2007 Jan; 17(1):53-6. PubMed ID: 17198933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p66ShcA modulates oxidative stress and survival of endothelial progenitor cells in response to high glucose.
    Di Stefano V; Cencioni C; Zaccagnini G; Magenta A; Capogrossi MC; Martelli F
    Cardiovasc Res; 2009 Jun; 82(3):421-9. PubMed ID: 19261622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic enhancement of p66Shc during cellular replicative or premature senescence.
    Zhang W; Ji W; Yang L; Xu Y; Yang J; Zhuang Z
    Toxicology; 2010 Dec; 278(2):189-94. PubMed ID: 20667496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human genetics of diabetic vascular complications.
    Tang ZH; Fang Z; Zhou L
    J Genet; 2013 Dec; 92(3):677-94. PubMed ID: 24371189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury.
    Spescha RD; Shi Y; Wegener S; Keller S; Weber B; Wyss MM; Lauinger N; Tabatabai G; Paneni F; Cosentino F; Hock C; Weller M; Nitsch RM; Lüscher TF; Camici GG
    Eur Heart J; 2013 Jan; 34(2):96-103. PubMed ID: 23008506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p66(shc) is highly expressed in fibroblasts from centenarians.
    Pandolfi S; Bonafè M; Di Tella L; Tiberi L; Salvioli S; Monti D; Sorbi S; Franceschi C
    Mech Ageing Dev; 2005 Aug; 126(8):839-44. PubMed ID: 15992607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity.
    Remely M; Aumueller E; Merold C; Dworzak S; Hippe B; Zanner J; Pointner A; Brath H; Haslberger AG
    Gene; 2014 Mar; 537(1):85-92. PubMed ID: 24325907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When p66ShcA is away, mice EPCs sweetly play.
    Sainz J; Sata M
    Cardiovasc Res; 2009 Jun; 82(3):388-9. PubMed ID: 19351737
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of p66Shc deletion in age-associated arterial dysfunction and disease states.
    Camici GG; Cosentino F; Tanner FC; Lüscher TF
    J Appl Physiol (1985); 2008 Nov; 105(5):1628-31. PubMed ID: 18772327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic Mechanisms in Diabetic Vascular Complications and Metabolic Memory: The 2020 Edwin Bierman Award Lecture.
    Natarajan R
    Diabetes; 2021 Feb; 70(2):328-337. PubMed ID: 33472942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics of macrovascular complications in diabetes.
    Fumeron F; Reis AF; Velho G
    Curr Diab Rep; 2006 Apr; 6(2):162-8. PubMed ID: 16542628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting chromatin remodeling to prevent cardiovascular disease in diabetes.
    Costantino S; Paneni F; Cosentino F
    Curr Pharm Biotechnol; 2015; 16(6):531-43. PubMed ID: 25860064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic Remodeling in Obesity-Related Vascular Disease.
    Masi S; Ambrosini S; Mohammed SA; Sciarretta S; Lüscher TF; Paneni F; Costantino S
    Antioxid Redox Signal; 2021 May; 34(15):1165-1199. PubMed ID: 32808539
    [No Abstract]   [Full Text] [Related]  

  • 39. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetics: mechanisms and implications for diabetic complications.
    Cooper ME; El-Osta A
    Circ Res; 2010 Dec; 107(12):1403-13. PubMed ID: 21148447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.